ES2237425T3 - Uso de glucosaminoglicanos en el tratamiento de la demencia senil. - Google Patents
Uso de glucosaminoglicanos en el tratamiento de la demencia senil.Info
- Publication number
- ES2237425T3 ES2237425T3 ES00925281T ES00925281T ES2237425T3 ES 2237425 T3 ES2237425 T3 ES 2237425T3 ES 00925281 T ES00925281 T ES 00925281T ES 00925281 T ES00925281 T ES 00925281T ES 2237425 T3 ES2237425 T3 ES 2237425T3
- Authority
- ES
- Spain
- Prior art keywords
- glycosaminoglycans
- molecular weight
- treatment
- heparin
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 36
- 238000011282 treatment Methods 0.000 title claims abstract description 31
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 21
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 37
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920000669 heparin Polymers 0.000 claims abstract description 21
- 229960002897 heparin Drugs 0.000 claims abstract description 20
- 210000004556 brain Anatomy 0.000 claims abstract description 15
- 208000014674 injury Diseases 0.000 claims abstract description 10
- 230000001537 neural effect Effects 0.000 claims abstract description 8
- 230000008733 trauma Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 10
- 238000002523 gelfiltration Methods 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 101100424823 Arabidopsis thaliana TDT gene Proteins 0.000 claims 1
- 230000003902 lesion Effects 0.000 abstract description 9
- 239000000243 solution Substances 0.000 description 43
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 241000700159 Rattus Species 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000002490 cerebral effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 7
- 210000002741 palatine tonsil Anatomy 0.000 description 7
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 6
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 6
- 108090000054 Syndecan-2 Proteins 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091016585 CD44 antigen Proteins 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001858 anti-Xa Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 229960001412 pentobarbital Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007514 neuronal growth Effects 0.000 description 3
- 230000002887 neurotoxic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000019635 sulfation Effects 0.000 description 3
- 238000005670 sulfation reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010056677 Nerve degeneration Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 150000007513 acids Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 230000001371 heparinic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- CWGBFIRHYJNILV-UHFFFAOYSA-N (1,4-diphenyl-1,2,4-triazol-4-ium-3-yl)-phenylazanide Chemical compound C=1C=CC=CC=1[N-]C1=NN(C=2C=CC=CC=2)C=[N+]1C1=CC=CC=C1 CWGBFIRHYJNILV-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091071247 Beta family Proteins 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 240000001970 Raphanus sativus var. sativus Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- DOIXGGGORNAJAT-UHFFFAOYSA-M [NH4+].[Ni+].[O-]S([O-])(=O)=O Chemical compound [NH4+].[Ni+].[O-]S([O-])(=O)=O DOIXGGGORNAJAT-UHFFFAOYSA-M 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- DAPUDVOJPZKTSI-UHFFFAOYSA-L ammonium nickel sulfate Chemical compound [NH4+].[NH4+].[Ni+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DAPUDVOJPZKTSI-UHFFFAOYSA-L 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229940105756 coagulation factor x Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 150000002302 glucosamines Chemical class 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI001066A IT1312107B1 (it) | 1999-05-14 | 1999-05-14 | Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile |
| ITMI991066 | 1999-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2237425T3 true ES2237425T3 (es) | 2005-08-01 |
Family
ID=11382970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00925281T Expired - Lifetime ES2237425T3 (es) | 1999-05-14 | 2000-05-12 | Uso de glucosaminoglicanos en el tratamiento de la demencia senil. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6979680B1 (enExample) |
| EP (1) | EP1181024B1 (enExample) |
| JP (1) | JP2002544233A (enExample) |
| KR (1) | KR100711142B1 (enExample) |
| CN (1) | CN1178667C (enExample) |
| AT (1) | ATE288761T1 (enExample) |
| AU (1) | AU764743C (enExample) |
| CA (1) | CA2373975A1 (enExample) |
| CZ (1) | CZ20014092A3 (enExample) |
| DE (1) | DE60018061T2 (enExample) |
| DK (1) | DK1181024T3 (enExample) |
| ES (1) | ES2237425T3 (enExample) |
| HK (1) | HK1039903B (enExample) |
| HU (1) | HUP0201100A3 (enExample) |
| IL (1) | IL146458A0 (enExample) |
| IT (1) | IT1312107B1 (enExample) |
| NO (1) | NO328902B1 (enExample) |
| PL (1) | PL198016B1 (enExample) |
| PT (1) | PT1181024E (enExample) |
| RU (1) | RU2248800C2 (enExample) |
| WO (1) | WO2000069444A1 (enExample) |
| ZA (1) | ZA200109331B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1344781A1 (en) * | 2002-03-12 | 2003-09-17 | Laboratori Derivati Organici S.P.A. | Process for the depolymerization of glycosaminoglycanes and products obtained therefrom |
| ITMI20031023A1 (it) * | 2003-05-21 | 2004-11-22 | Umberto Cornelli | Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali. |
| EP1524276A1 (en) * | 2003-10-16 | 2005-04-20 | Laboratori Derivati Organici S.P.A. | Multistep process for the physical depolymerization of heparin and products obtained therefrom |
| US7939512B2 (en) | 2004-10-13 | 2011-05-10 | Laboratori Derivati Organici Spa | Multistep process for the physical depolymerization of heparin and products obtained therefrom |
| DE602006016990D1 (de) | 2005-12-22 | 2010-10-28 | Bellus Health Int Ltd | Behandlung von diabetischer nephropathie |
| WO2009007224A1 (en) * | 2007-07-10 | 2009-01-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Low molecular weight heparin derivatives having neuroprotective activity |
| US8896239B2 (en) | 2008-05-22 | 2014-11-25 | Vladimir Yegorovich Balakin | Charged particle beam injection method and apparatus used in conjunction with a charged particle cancer therapy system |
| CN102119586B (zh) | 2008-05-22 | 2015-09-02 | 弗拉迪米尔·叶戈罗维奇·巴拉金 | 多场带电粒子癌症治疗方法和装置 |
| JP5450602B2 (ja) | 2008-05-22 | 2014-03-26 | エゴロヴィチ バラキン、ウラジミール | シンクロトロンによって加速された荷電粒子を用いて腫瘍を治療する腫瘍治療装置 |
| EP2283713B1 (en) | 2008-05-22 | 2018-03-28 | Vladimir Yegorovich Balakin | Multi-axis charged particle cancer therapy apparatus |
| US8841866B2 (en) | 2008-05-22 | 2014-09-23 | Vladimir Yegorovich Balakin | Charged particle beam extraction method and apparatus used in conjunction with a charged particle cancer therapy system |
| SG173879A1 (en) | 2009-03-04 | 2011-10-28 | Protom Aozt | Multi-field charged particle cancer therapy method and apparatus |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| ES2675993T3 (es) * | 2011-10-14 | 2018-07-16 | Centre National De La Recherche Scientifique | Procedimiento de diagnóstico, pronóstico o tratamiento de enfermedades neurodegenerativas |
| CN112426434A (zh) * | 2020-11-04 | 2021-03-02 | 山东大学 | 硫酸乙酰肝素在防治阿尔兹海默症中的应用 |
| CN114478816A (zh) * | 2022-02-11 | 2022-05-13 | 上海兴糖生物技术有限公司 | 一种白玉蜗牛多糖及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4351938A (en) * | 1980-05-19 | 1982-09-28 | Riker Laboratories, Inc. | Anticoagulant substance |
| US4847338A (en) * | 1985-03-28 | 1989-07-11 | University Of Iowa Research Foundation | Low molecular weight heparin fragments as inhibitors of complement activation |
| EP0243974B1 (en) * | 1986-05-01 | 1994-03-02 | Toppan Printing Co., Ltd. | Scanner set-up simulation apparatus |
| IT1213384B (it) * | 1986-11-24 | 1989-12-20 | Lab Derivati Organici Mediolan | Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare. |
| IT1205042B (it) * | 1987-05-28 | 1989-03-10 | Crinos Industria Farmaco | Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer |
| EP0337327A1 (en) * | 1988-04-09 | 1989-10-18 | Bioiberica, S.A. | Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin |
| IT1240615B (it) * | 1990-04-03 | 1993-12-17 | Mediolanum Farmaceutici Spa | Impiego del dermatan solfato nella prevenzione e terapia dell'invecchiamento cerebrale e degli stati di deficit funzionale del sistema nervoso centrale |
| IL100555A (en) * | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
| SK279285B6 (sk) * | 1991-05-02 | 1998-09-09 | Daiichi Pharmaceutical Co. | Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin |
| RU2106864C1 (ru) * | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
-
1999
- 1999-05-14 IT IT1999MI001066A patent/IT1312107B1/it active
-
2000
- 2000-05-12 AU AU44052/00A patent/AU764743C/en not_active Ceased
- 2000-05-12 EP EP00925281A patent/EP1181024B1/en not_active Expired - Lifetime
- 2000-05-12 CZ CZ20014092A patent/CZ20014092A3/cs unknown
- 2000-05-12 IL IL14645800A patent/IL146458A0/xx not_active IP Right Cessation
- 2000-05-12 DK DK00925281T patent/DK1181024T3/da active
- 2000-05-12 AT AT00925281T patent/ATE288761T1/de not_active IP Right Cessation
- 2000-05-12 ES ES00925281T patent/ES2237425T3/es not_active Expired - Lifetime
- 2000-05-12 HK HK02101550.8A patent/HK1039903B/en not_active IP Right Cessation
- 2000-05-12 HU HU0201100A patent/HUP0201100A3/hu unknown
- 2000-05-12 RU RU2001130882/14A patent/RU2248800C2/ru not_active IP Right Cessation
- 2000-05-12 DE DE60018061T patent/DE60018061T2/de not_active Expired - Fee Related
- 2000-05-12 CN CNB00807562XA patent/CN1178667C/zh not_active Expired - Fee Related
- 2000-05-12 PT PT00925281T patent/PT1181024E/pt unknown
- 2000-05-12 US US10/048,542 patent/US6979680B1/en not_active Expired - Fee Related
- 2000-05-12 JP JP2000617903A patent/JP2002544233A/ja active Pending
- 2000-05-12 PL PL352070A patent/PL198016B1/pl not_active IP Right Cessation
- 2000-05-12 KR KR1020017014505A patent/KR100711142B1/ko not_active Expired - Fee Related
- 2000-05-12 CA CA002373975A patent/CA2373975A1/en not_active Abandoned
- 2000-05-12 WO PCT/EP2000/004311 patent/WO2000069444A1/en not_active Ceased
-
2001
- 2001-11-13 NO NO20015544A patent/NO328902B1/no not_active IP Right Cessation
- 2001-11-13 ZA ZA200109331A patent/ZA200109331B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO328902B1 (no) | 2010-06-14 |
| DE60018061D1 (de) | 2005-03-17 |
| EP1181024A1 (en) | 2002-02-27 |
| NO20015544D0 (no) | 2001-11-13 |
| CN1178667C (zh) | 2004-12-08 |
| HK1039903A1 (en) | 2002-05-17 |
| AU4405200A (en) | 2000-12-05 |
| HK1039903B (en) | 2005-08-26 |
| HUP0201100A2 (hu) | 2002-07-29 |
| AU764743B2 (en) | 2003-08-28 |
| AU764743C (en) | 2004-03-18 |
| CZ20014092A3 (cs) | 2002-04-17 |
| PL352070A1 (en) | 2003-07-28 |
| PT1181024E (pt) | 2005-06-30 |
| CA2373975A1 (en) | 2000-11-23 |
| IT1312107B1 (it) | 2002-04-04 |
| ATE288761T1 (de) | 2005-02-15 |
| HUP0201100A3 (en) | 2003-03-28 |
| PL198016B1 (pl) | 2008-05-30 |
| NO20015544L (no) | 2002-01-14 |
| US6979680B1 (en) | 2005-12-27 |
| EP1181024B1 (en) | 2005-02-09 |
| DK1181024T3 (da) | 2005-06-13 |
| CN1350459A (zh) | 2002-05-22 |
| DE60018061T2 (de) | 2006-04-13 |
| ITMI991066A1 (it) | 2000-11-14 |
| KR100711142B1 (ko) | 2007-04-24 |
| KR20020005033A (ko) | 2002-01-16 |
| JP2002544233A (ja) | 2002-12-24 |
| ZA200109331B (en) | 2002-08-28 |
| RU2248800C2 (ru) | 2005-03-27 |
| IL146458A0 (en) | 2002-07-25 |
| WO2000069444A1 (en) | 2000-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2237425T3 (es) | Uso de glucosaminoglicanos en el tratamiento de la demencia senil. | |
| Plant et al. | Inhibitory proteoglycan immunoreactivity is higher at the caudal than the rostral Schwann cell graft-transected spinal cord interface | |
| ES2231880T3 (es) | Procedimiento para tratar el asma con heparina o-desulfatada. | |
| JPS6214271B2 (enExample) | ||
| JPS63213502A (ja) | 低分子量グルコサミノグルカンの制御製造方法 | |
| US20080299212A1 (en) | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum | |
| JP3264560B2 (ja) | 急性末梢神経障害治療用組成物 | |
| ES2205114T3 (es) | Fucanos con bajo peso molecular que tienen actividad anticoagulante, antitrombinica y antitrombotica. | |
| CN1794999B (zh) | 神经损伤治疗剂 | |
| JPS62174027A (ja) | 改良されたキモパパイン及び製薬学的組成物 | |
| AP619A (en) | Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction. | |
| CZ284739B6 (cs) | Diagnostický prostředek pro vyšetření ledvin | |
| ES2734182T3 (es) | Acido polisiálico y su uso para el tratamiento de enfermedades neurodegenerativas y neuroinflamatorias | |
| US20220380331A1 (en) | Treatment of conditions of the nervous system | |
| JPH10503168A (ja) | 神経系の損傷の処置のための置換デキストランの使用ならびにヘパラン硫酸に富む分画 | |
| KR100531721B1 (ko) | 중추 신경계 외상 예방과 치료를 위한 저분자량 헤파린의사용 | |
| JP2002502387A (ja) | 脳水腫の予防及び処置のための低−分子量ヘパリンの使用 | |
| EP0065395A2 (en) | Improved chymopapain and method for its production and use | |
| EA046226B1 (ru) | Применение фармацевтической композиции в качестве лекарственного средства для защиты и/или репарации/восстановления гематоэнцефалического барьера | |
| Krzywkowski | Céline Morissette, Diane Lacombe, Xianqi Kong, Ahmed Aman, Pascale Krzywkowski, Lioudmila Rodionova, Mounia Azzi, Daniel Delorme, and Barry D. Greenberg | |
| CA2219683A1 (en) | Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration | |
| JPH04173744A (ja) | 神経細胞保護剤 |